Overview

Safety and Efficacy Study of TLL018 in the Treatment of Ulcerative Colitis

Status:
Not yet recruiting
Trial end date:
2023-12-30
Target enrollment:
Participant gender:
Summary
A study to investigate the safety and efficacy of TLL018 compared with placebo in subjects with moderate to severe ulcerative colitis.
Phase:
Phase 2
Details
Lead Sponsor:
Hangzhou Highlightll Pharmaceutical Co., Ltd
Collaborator:
TLL Pharmaceutical, LLC